Actas urologicas espanolas最新文献

{"title":"Factores preoperatorios predictivos del incremento a estadio patológico T3a y márgenes quirúrgicos positivos en el carcinoma de células renales en estadio clínico T1","authors":"G. Çil,&nbsp;M. Yilmaz,&nbsp;Y. Sahin,&nbsp;İ. Ulus,&nbsp;İ.O. Canıtez,&nbsp;İ.E. Kandıralı","doi":"10.1016/j.acuro.2023.09.006","DOIUrl":"10.1016/j.acuro.2023.09.006","url":null,"abstract":"<div><h3>Objectives</h3><p>The objective of this study is predict positive surgical margin (PSM) and pathological T3a (pT3a) upstaging in patients with clinical T1 (cT1) renal cell carcinoma (RCC).</p></div><div><h3>Materials and Methods</h3><p>159 patients who underwent radical nephrectomy (RN) or partial nephrectomy (PN) for RCC. Patients’ demographic, laboratory, radiological and pathological data that could predict PSM and pT3a upstaging pre-operatively were evaluated. The categorical and continuous variables were compared between the patient groups with or without PSM and/or pT3a upstaging using Pearson's chi-square test, and independent samples t-test or the Mann-Whitney U test, respectively.</p></div><div><h3>Results</h3><p>PT3a upstaging was detected in 32 (20.1%) patients, and PSM was detected in 28 (17.6%) patients. PT3a upstaging was detected in 27 and 5 patients who underwent open surgery and laparoscopic surgery, respectively (p<!--> <!-->&lt;<!--> <!-->0.001). In addition, pT3a upstaging was detected in 6 and 26 patients who underwent RN and PN, respectively (p<!--> <!-->&lt;<!--> <!-->0.001). Peritumoral fatty tissue thickness was 11.97 and 15.38 in the pT1 and pT3a patient groups, respectively (p<!--> <!-->=<!--> <!-->0.022). In patients with pT3a upstaging, tumor size was larger, and renal nephrometry score and systemic immune-inflammation index (SII) were higher (p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->&lt;<!--> <!-->0.001, and p<!--> <!-->=<!--> <!-->0.022, respectively). It was determined that De Ritis ratio (DRR) and albumin-to-alkaline phosphatase (ALP) ratio (AAPR) parameters had significant prognostic values in predicting PSM (p<!--> <!-->=<!--> <!-->0.024, and p<!--> <!-->=<!--> <!-->0.001, respectively). ROC analysis indicated that tumor size predicted pT3a upstaging with 100% sensitivity and 98.6% specificity when its cut-off value was taken as 6.85<!--> <!-->mm (AUC: 1.000, p<!--> <!-->&lt;<!--> <!-->0.001). In addition, logistic regression analysis revealed AAPR and DRR as significant predictors of PSM (p<!--> <!-->&lt;<!--> <!-->0.001, and p<!--> <!-->=<!--> <!-->0.009, respectively).</p></div><div><h3>Conclusion</h3><p>The findings of this study indicated that the surgical technique of choice and the type of operation, tumor size, RNS value, peritumoral fatty tissue thickness, HU values of peritumoral and tumor side fatty tissues, and DRR and SII values can predict pT3a upstaging of patients with cT1 RCC, and that AAPR and DRR values can predict PSM.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 4","pages":"Pages 311-318"},"PeriodicalIF":1.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seguridad y eficacia del nivolumab para el tratamiento de pacientes con carcinoma de células renales metastásico e insuficiencia renal","authors":"N. Sengul ,&nbsp;I. Gültürk ,&nbsp;M. Yilmaz ,&nbsp;E. Celik ,&nbsp;N. Paksoy ,&nbsp;E. Yekedüz ,&nbsp;Y. Ürün ,&nbsp;M. Basaran ,&nbsp;M. Özgüroğlu","doi":"10.1016/j.acuro.2024.01.014","DOIUrl":"10.1016/j.acuro.2024.01.014","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with renal insufficiency, usually defined as those with creatinine clearance<!--> <!-->&lt;<!--> <!-->40<!--> <!-->mL/min, were excluded from pivotal clinical trials, especially in studies involving nivolumab therapy in patients with renal cell carcinoma (RCC).The aim of the study is to evaluate the efficacy and safety of nivolumab in patients with metastatic RCC (mRCC) stratified according to creatinine clearance.</p></div><div><h3>Material and metods</h3><p>Data from mRCC patients treated with nivolumab were retrospectively analyzed. Patients were classified into two categories according to their estimated glomerular filtration rate (eGFR); the first category (C1) included patients with eGFR<!--> <!-->&lt;<!--> <!-->40<!--> <!-->mL/min/1.73 m² and the second category(<span>C</span>2). included those with eGFR≥ 40<!--> <!-->mL/min/1.73 m^2.</p></div><div><h3>Results</h3><p>Of the 95 patients enrolled, 1. group included 26 patients (27.4%) and 2. group included 69 patients (72.6%). None of the pts in category 1 were on hemodialysis. Overall incidence of adverse events was not statistically different between the two groups (p<!--> <!-->=<!--> <!-->0.469). The overall response rate ORR was 50% in the first group and 42.0% in the second group (p<!--> <!-->=<!--> <!-->0.486). Median overall survival (OS) was longer with 23.3 months in the 2. group versus 11 months in the 1. group (p<!--> <!-->=<!--> <!-->0.415).</p></div><div><h3>Conclusion</h3><p>Renal insufficiency is a common problem in patients with advanced renal cancer since they often undergo nephrectomy and their renal function may also worsen while receiving tyrosine kinase inhibitor therapy. We found that there is no significant difference in the safety and efficacy of nivolumab treatment between two groups. Nivolumab appears to be a safe and effective agent in patients with renal impairment.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 4","pages":"Pages 273-280"},"PeriodicalIF":1.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140084295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivel líquido-grasa intravesical como señal de alerta de perforación vesical contenida: correlación entre los hallazgos de la cistoscopia y la tomografía computarizada","authors":"P. Montosa Ródenas ,&nbsp;M. Gómez Huertas ,&nbsp;M.A. Pérez Rosillo ,&nbsp;A.J. Láinez Ramos-Bossini","doi":"10.1016/j.acuro.2023.07.007","DOIUrl":"10.1016/j.acuro.2023.07.007","url":null,"abstract":"","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 254-256"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49201254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación entre el polimorfismo de los genes LHCGR y NR5A1y el riesgo de infertilidad masculina","authors":"M. Behvarz ,&nbsp;S.A. Rahmani ,&nbsp;E. Siasi Torbati ,&nbsp;S. Danaei Mehrabad ,&nbsp;M. Bikhof Torbati","doi":"10.1016/j.acuro.2023.08.002","DOIUrl":"10.1016/j.acuro.2023.08.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Infertility is one of the important phenomena in human reproduction. Genetic factors are the most important cause of male infertility. Here, we aimed to investigate the correlation between idiopathic male infertility and SNPs of the <em>LHCGR</em> (rs2293275) and <em>NR5A1</em> (rs1057517779) genes in the Iranian-Azeri population.</p></div><div><h3>Methods</h3><p>This case-control study consisted of 100 males with infertility and 100 healthy males from the Iranian Azeri population. Genomic DNA isolation from whole blood samples and Tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR) method was used for genotyping. The data analysis was performed by Chi-square (χ²) and Fisher's exact tests.</p></div><div><h3>Results</h3><p>Genotyping analysis for <em>LHCGR</em> (rs2293275) polymorphism indicated that the frequency of C in the case group was significantly higher than in the control group (<em>P</em>&lt;.05). Moreover, genotyping analysis for <em>NR5A1</em> (rs1057517779) polymorphism indicated that the frequencies of the A allele and heterozygote GA genotype in the case group were significantly higher than those in the control group (<em>P</em>&lt;.05).</p></div><div><h3>Conclusion</h3><p>Our study demonstrated that the SNPs of <em>LHCGR</em> (rs2293275) and <em>NR5A1</em> (rs1057517779) genes may play a critical role in male infertility in the Iranian Azeri population. However, further studies on other ethnic origins with larger sample sizes are essential for accessing more accurate results. Moreover, functional experiments might be needed to understand the role of these polymorphisms in the molecular pathways involved in male fertility.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 246-253"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135255100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacto del uso de la vaina de acceso ureteral durante la ureteroscopia flexible: estudio comparativo de eficacia y seguridad","authors":"M.M. Abdelfatah Zaza ,&nbsp;A. Farouk Salim ,&nbsp;T.A. El-Mageed Salem ,&nbsp;A. Mohammed Ezzat ,&nbsp;M. Hassan Ali","doi":"10.1016/j.acuro.2023.08.005","DOIUrl":"10.1016/j.acuro.2023.08.005","url":null,"abstract":"<div><h3>Objectives</h3><p>This study evaluates the impact of using an access sheath (AS) during flexible ureteroscopy (fURS) for urolithiasis treatment, focusing on outcomes such as stone-free rate, operation time, and complications.</p></div><div><h3>Methods</h3><p>This prospective, randomized study was carried out at Badr Hospital, Helwan University, and Ain Shams University hospitals from August 2021 to August 2022. Patients were systematically randomized into two groups (fURS with AS: 33 patients and without AS: 31 patients) and underwent preoperative and postoperative assessments, including lab tests and imaging. Possible procedure-associated risks, such as failed stone access, pain, bleeding, and sepsis, were monitored.</p></div><div><h3>Results</h3><p>The two groups were found to be comparable in terms of demographic characteristics or preoperative stone findings (<em>P</em>&gt;.05 for all). However, operation duration was shorter in the No Sheath group (79.4<!--> <!-->±<!--> <!-->15.3<!--> <!-->minutes vs. 90.4<!--> <!-->±<!--> <!-->16.7<!--> <!-->minutes in the Sheath group, <em>P</em>=.008). Intraoperative complication rates, including failed access, operation termination, ureteric injury, and bleeding, were comparable in both groups (<em>P</em>&gt;.05). Postoperative stone-free rates (78.8% vs. 71.0%, <em>P</em>=.305) and mean residual stone size (2.7<!--> <!-->±<!--> <!-->3.5<!--> <!-->mm vs. 3.1<!--> <!-->±<!--> <!-->3.1<!--> <!-->mm, <em>P</em>=.687) showed no significant differences.</p></div><div><h3>Conclusions</h3><p>The present study suggests that fURS without an access sheath may offer an efficient and equally effective option for managing upper ureteric and renal stones. However, more studies with larger sample sizes and longer follow-up periods are required to validate these findings and to establish more precise indications for this approach.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 204-209"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135389817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación del valor predictivo negativo de la resonancia magnética multiparamétrica de próstata al combinar su puntuación con parámetros del antígeno prostático específico en pacientes con PSA en zona gris","authors":"C. Bostancı,&nbsp;D.Ö. Demir","doi":"10.1016/j.acuro.2023.08.001","DOIUrl":"10.1016/j.acuro.2023.08.001","url":null,"abstract":"<div><h3>Objective</h3><p>To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.</p></div><div><h3>Methods</h3><p>One hundred ninety-one patients with PSA levels between 4-10<!--> <!-->mg/ml and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of &lt;0.15 ng/ml/ml, f/t PSA ratio of &gt;0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters:</p><ul><li><span>•</span><span><p>PSAD 0.01-0.07 ng/ml/ml and f/t PSA ratio ≥25 in a low-risk group.</p></span></li><li><span>•</span><span><p>PSAD 0.08-0.15 ng/ml/ml, and f/t PSA ratio 0.15-0.24 in an intermediate-risk group and high-risk group.</p></span></li><li><span>•</span><span><p>PSAD&gt;0.15 ng/ml/ml and f/t PSA ratio &lt;15 in high-risk group,</p></span></li></ul></div><div><h3>Results</h3><p>NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD &lt;0.15 ng/ml/ml and f/t PSA&gt;15.</p></div><div><h3>Conclusion</h3><p>f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is &gt;0.15 ng/ml/ml and the f/t PSA ratio is &lt;0.15. However, we need randomized controlled studies with more patients to confirm our study.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 238-245"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135255122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparación entre las calculadoras de riesgo del European Randomized Study for Screening of Prostate Cancer (ERSPC) y Prostate Biopsy Collaborative Group (PBCG): predicción del riesgo de cáncer de próstata clínicamente significativo en una cohorte de pacientes de Argentina","authors":"P.M. Orbe Villota ,&nbsp;J.A. Leiva Centeno ,&nbsp;J. Lugones ,&nbsp;P.G. Minuzzi ,&nbsp;S.M. Varea","doi":"10.1016/j.acuro.2023.07.008","DOIUrl":"10.1016/j.acuro.2023.07.008","url":null,"abstract":"<div><h3>Objective</h3><p>To compare the performance of the risk calculators of the European Randomized Study for Screening of Prostate Cancer (ERSPC) and the Prostate Biopsy Collaborative Group (PBCG) in predicting the risk of presenting clinically significant prostate cancer.</p></div><div><h3>Material and methods</h3><p>Retrospectively, patients who underwent prostate biopsy at Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, were identified from January 2018 to December 2021. The probability of having prostate cancer was calculated with the two calculators separately and then the results were compared to establish which of the two performed better. For this, areas under the curve (AUC) were analyzed.</p></div><div><h3>Results</h3><p>250 patients were included, 140 (56%) presented prostate cancer, of which 92 (65.71%) had clinically significant prostate cancer (Gleason score ≥<!--> <!-->7). The patients who presented cancer were older, had a higher prostate-specific antigen (PSA) value, and had a smaller prostate size. The AUC to predict the probability of having clinically significant prostate cancer was 0.79 and 0.73 for PBCG-RC and ERSPC-RC respectively (p<!--> <!-->=<!--> <!-->0.0084).</p></div><div><h3>Conclusion</h3><p>In this cohort of patients, both prostate cancer risk calculators performed well in predicting clinically significant prostate cancer risk, although the PBCG-RC showed better accuracy.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 210-217"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"53918926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalencia del cáncer del tracto urinario. Análisis de la cohorte española del estudio IDENTIFY","authors":"C. Toribio-Vázquez ,&nbsp;J. Gómez Rivas ,&nbsp;F. Amigo ,&nbsp;D.M. Carrión ,&nbsp;Á. Yebes ,&nbsp;M. Alonso-Bartolomé ,&nbsp;H. Ayllon ,&nbsp;A. Aguilera ,&nbsp;L. Martinez-Pineiro ,&nbsp;M. Antón-Juanilla ,&nbsp;V. Crespo-Atín ,&nbsp;H. Otaola-Arca ,&nbsp;J.A. Herranz-Yague ,&nbsp;M.V. Munoz Rivero ,&nbsp;K.R. MacKenzie ,&nbsp;T.T. Shah ,&nbsp;C. Gao ,&nbsp;E. Zimmermann ,&nbsp;M. Jefferies ,&nbsp;A. Nambiar ,&nbsp;V. Kasivisvanathan","doi":"10.1016/j.acuro.2023.06.004","DOIUrl":"10.1016/j.acuro.2023.06.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Malignant tumors of the urinary tract are associated with high morbidity and mortality, and their prevalence can vary worldwide. Recently, the IDENTIFY study has published results on the prevalence of urinary tract cancer at a global level. This study evaluates the prevalence of cancer within the Spanish cohort of the IDENTIFY study to determine whether the published results can be extrapolated to our population.</p></div><div><h3>Patients and methods</h3><p>An analysis of the data from the Spanish cohort of patients in the IDENTIFY study was performed. This is a prospective cohort of patients referred to secondary care with suspected cancer, predominantly due to hematuria. Patients were recruited between December 2017 and December 2018.</p></div><div><h3>Results</h3><p>A total of 706 patients from 9 Spanish centers were analyzed. Of these, 277 (39.2%) were diagnosed with cancer: 259 (36.7%) bladder cancer, 10 (1.4%) upper tract urothelial carcinoma, 9 (1.2%) renal cancer and 5 (0.7%) prostate cancer. Increasing age (OR: 1.05; 95% CI: 1.03-1.06; <em>P</em>&lt;.001), visible hematuria (VH) OR: 2.19; 95% CI: 1.13-4.24; <em>P</em>=.02)and smoking (ex-smokers: OR: 2.11; 95% CI: 1.30-3.40; <em>P</em>=.002); (smokers: OR: 2.36; 95% CI: 1.40-3.95; <em>P</em>=.001) were associated with higher probability of bladder cancer.</p></div><div><h3>Conclusion</h3><p>This study highlights the risk of bladder cancer in patients with VH and smoking habits. Bladder cancer presented the highest prevalence; higher than the prevalence reported in previous series and presented in the IDENTIFY study. Future work should evaluate other associated factors that allow us to create cancer prediction models to improve the detection of cancer in our patients.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 228-237"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47607587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La relación entre infertilidad y calidad del sueño en las mujeres: revisión sistemática y metaanálisis","authors":"N. Gençtürk ,&nbsp;A. Yıldız Karaahmet ,&nbsp;S. Shafaati Laleh ,&nbsp;Z. Guksu","doi":"10.1016/j.acuro.2023.08.006","DOIUrl":"10.1016/j.acuro.2023.08.006","url":null,"abstract":"<div><h3>Objectives</h3><p>This systematic review and meta-analysis study aimed to examine the relationship between infertility and sleep quality in women.</p></div><div><h3>Methods</h3><p>The literature search was conducted between October and November 2022 with full-text studies from PubMed (MEDLINE), Cochrane, Google Scholar, and Scientific Information Database (SID). The study is based on the recommendations of the Cochrane guidelines. The data were analyzed using the Review Manager computer software (Version 5.3).</p></div><div><h3>Results</h3><p>A systematic literature review was conducted, with 11 studies included. The meta-analysis revealed a significant difference between infertility and sleep quality in women, that the sleep quality of infertile patients decreased (SMD: -0.75 95% CI: -0.84 to -0.66, Z<!--> <!-->=<!--> <!-->16.46, <em>P</em>&lt;.00001), and that there was a significant difference between infertility and depression (SMD: -0.18 95% CI: -0.27 to -0.09, Z<!--> <!-->=<!--> <!-->4.00, <em>P</em>&lt;.0001).</p></div><div><h3>Conclusion</h3><p>The results of this study indicate that sleep quality is low in infertile women.</p><p>PROSPERO ID: CRD42023404389.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 185-203"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135588941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manejo de los pacientes con cáncer de próstata localizado y recurrencia bioquímica en España: encuesta médica","authors":"R. Correa ,&nbsp;N. Vidal ,&nbsp;A. Quesada-García ,&nbsp;R. Marcos ,&nbsp;J. Muñoz del Toro ,&nbsp;J. Muñoz-Rodríguez","doi":"10.1016/j.acuro.2023.06.003","DOIUrl":"10.1016/j.acuro.2023.06.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.</p></div><div><h3>Objectives</h3><p>To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with biochemical recurrence (BCR) in Spain.</p></div><div><h3>Materials and methods</h3><p>A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).</p></div><div><h3>Results</h3><p>The annual incidence of PCa was 24,057 in participating hospitals (N<!--> <!-->=<!--> <!-->131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79 and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the 3 specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.</p></div><div><h3>Conclusion</h3><p>This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.</p></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 218-227"},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0210480623000955/pdfft?md5=523c6f3a4608c47ad8b93b5342142ce7&pid=1-s2.0-S0210480623000955-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48003109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}